Navigation Links
Tengion Scientists Publish Key Preclinical Findings Demonstrating the Benefits of Organ Regeneration Vs. Repair
Date:6/12/2008

Study Showing Results of Tengion Neo-Bladder Augment(TM) to be Featured in

July Issue of the Journal of Urology

EAST NORRITON, Pa., June 12 /PRNewswire/ -- Tengion, Inc., a clinical stage biotechnology company focused on the development of neo-organs and neo-tissues, announced today that the results of a preclinical research study conducted with its Neo-Bladder Augment(R) will be featured in the July issue of the Journal of Urology, Vol. 180. The paper, "Early Cellular and Stromal Responses in Regeneration Versus Repair of a Mammalian Bladder Using Autologous Cell and Biodegradable Scaffold Technologies," was co-authored by Tengion scientists Manuel J. Jayo, D.V.M., Ph.D., Deepak Jain, Ph.D., Belinda J. Wagner, Ph.D. and Timothy A. Bertram, D.V.M., Ph.D.

Key findings of the preclinical trial -- in which either a Tengion Neo-Bladder Augment or a biodegradable mesh scaffold alone was surgically implanted following partial, trigone-sparing cystectomy and both groups were evaluated clinically at one, three, six and nine months -- show that the Tengion Neo-Bladder Augment restored baseline urodynamics as early as six months after implantation and led to a structurally and functionally complete regenerated bladder wall as early as nine months. In contrast, scaffold implants alone failed to return to urodynamic baseline by the study termination and failed to regenerate a complete bladder wall.

"We continue to see great promise in our neo-bladder research programs and these latest data underscore the potential of Tengion's Autologous Organ Regeneration Platform(TM) to provide a neo-organ that allows the body to regenerate a functional organ," said Dr. Bertram, Senior Vice President, Science and Technology of Tengion. "We are looking forward to formally sharing these findings with our peers and continuing to develop our Neo-Bladder Augment and the Tengion Neo-Bladder Replacement(R) to meet the critical patient needs that exist today."

About Tengion

Tengion, a clinical stage biotechnology company, focuses on developing, manufacturing and commercializing human neo-organs and neo-tissues using our Autologous Organ Regeneration Platform(TM). Tengion uses biocompatible materials and a patient's own (autologous) cells to create neo-organs or neo-tissues that are designed to catalyze the body's innate ability to regenerate. Tengion's product candidates may ultimately address the most critical problems facing organ and tissue failure patients, enabling people to lead healthier lives without donor transplants or the side effects of related therapies. For more information on the company and current clinical trials, visit Tengion online at: http://www.tengion.com.


'/>"/>
SOURCE Tengion, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Preclinical Data Demonstrate Ability to Regenerate an Entire Bladder With Tengion Neo-Bladder Replacement(TM)
2. Tengion Launches Third Phase 2 Clinical Trial of Regenerated Human Bladder
3. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
4. Brain Stem Cells Can Be Awakened, Say Schepens Scientists
5. Infant Vaccines Produce Autism Symptoms in New Primate Study by University of Pittsburgh Scientists
6. ImQuest Scientists Present Important HIV Microbicide Development Results at Microbicides 2008 in Delhi, India
7. Neuroscientists Offer Hope for Breast Cancer Patients Suffering From Chemobrain
8. Published Guidelines Further Support Use of Bioimpedance Measurement Technology for Early Assessment of Lymphedema
9. The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxters Cell-Based Pandemic, Avian Flu Vaccine
10. Biopure Phase III Orthopedic Trial Results Published in Journal of Trauma
11. Newly Published Study Shows OPKOs siRNA Bevasiranib Is Taken Up by Target Tissues in the Eye
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... -- UCB is pleased to announce that 12 scientific abstracts have ... American Epilepsy Society (AES) Annual Meeting, which takes place ... USA. 1-12 Data being presented include ... ® (lacosamide) CV and BRIVIACT ® (brivaracetam) CV. ... state of the union of epilepsy care and antiepileptic drugs ...
(Date:12/2/2016)... -- Allergan plc (NYSE: AGN ), a leading ... announced Accelerated Share Repurchase (ASR) Program. Logo - ... , ... announced, the Company entered into a variable tenor ASR arrangement ... $10 billion of its ordinary shares. Approximately 40.5 million shares ...
(Date:11/30/2016)... , Nov 30, 2016 Research and ... Intracranial Pressure Monitoring Devices 2017 - MedCore" report to their offering. ... , , ... brain and the skull. In healthy individuals, it is circulated though the ... are cases where the amount of CSF surrounding the brain changes significantly. ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... 2016 , ... Center for Autism and Related Disorders (CARD) Portland today announced ... disorder (ASD) and other developmental disabilities. The group, which is being launched with the ... the opportunity to share stories and advice, seek help, and continue their education on ...
(Date:12/2/2016)... ... 2016 , ... U.S. Surgeon General, Dr. Vivek Murthy, graces the cover of ... was inspired to practice medicine at an early age by his father, who was ... diagnoses and prescribing medicine,” he states. “It is about building relationships with people; relationships ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... two ostomy patients, standing as living proof that attitude and determination can combine ... and issues that spike around the holidays. This campaign will offer patients a ...
(Date:12/2/2016)... ... December 02, 2016 , ... More than half of American teens report losing ... report speaking with their child about sex related topics, less than 60 percent spoke ... proud to announce the launch of its second edition of the “Sexual Wellness” campaign, ...
(Date:12/2/2016)... ... 02, 2016 , ... CloudLIMS.com, a class-leading provider of Laboratory ... CloudLIMS Lite helps biobanks, clinical, research and testing laboratories keep track of their ... version is a faster and a more efficient product, allowing batch processing of ...
Breaking Medicine News(10 mins):